Tango Therapeutics (TNGX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
The meeting was called to order at 9:00 A.M. Eastern Time on June 4, 2026, and conducted virtually to increase inclusivity among stockholders.
The agenda included conducting business first, followed by a Q&A session after proposal presentations.
Board and executive committee updates
Introductions were made for outside directors and key management, including the CEO, CFO, President of R&D, and VP Legal.
Broadridge Financial Solutions acted as tabulator, and an Independent Inspector of Elections was appointed.
Shareholder proposals
Three proposals were presented: election of Class II directors, ratification of the independent auditor, and an advisory vote on executive compensation.
Votes for a resigned director nominee were disregarded.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Tango Therapeutics
- Frontline pancreatic Phase III is planned for H1 2027 after encouraging combination data.TNGX
3rd Annual Guggenheim Healthcare Innovation Conference - Pancreatic cancer data support a planned Phase 3 trial amid wider losses and $977.5M in liquidity.TNGX
Q3 2026 - Vopimetostat plus daraxonrasib achieved 82% ORR in PDAC ahead of planned Phase 3 testing.TNGX
Study result - Vopimetostat delivers breakthrough efficacy in cancer, with pivotal data and regulatory updates ahead.TNGX
12th Annual Cantor Fitzgerald Global Healthcare Conference - 92% response rate in pancreatic cancer drives Phase 3 plans; net loss rises, cash at $1.0B.TNGX
Q2 2026 - Vopimetostat and TNG456 show strong efficacy in MTAP-deleted cancers, with major milestones ahead.TNGX
Investor presentation - Vopimetostat plus pan-RAS inhibitors achieved a 92% response rate and strong tolerability in advanced pancreatic cancer.TNGX
Study result - Q1 2026 net loss reached $45.5M; $380M cash supports late-stage oncology trials into 2028.TNGX
Q1 2026 - PRMT5 inhibitors show strong efficacy in MTAP-deleted cancers, with pivotal trials and solid funding.TNGX
44th Annual J.P. Morgan Healthcare Conference